RESULTS FOR : 'Biologics'
Showing 1 to 9 of 9 results |    
Keyword Search
Results Category/Section
Cobra Biologics appoints Dr Darrell Sleep as Director of Innovation

Appointment will drive scientific and technical innovation to streamline process workflows and advance ATMP service offering

Cobra Biologics, Pall and the Cell and Gene Therapy Catapult Win 1.5M Grant

Cobra Biologics, Pall Corporation and the Cell and Gene Therapy Catapult Win 1.5M Innovate UK Grant to Investigate Continuous Manufacturing for Gene Therapies

Cobra Biologics and the University of Leeds Collaborate in BioProNET Funded Project

100K grant will fund proof-of-concept studies to optimise bioprocessing of gene therapy vectors using hydrodynamic fluid flow fields

Biologics Drug Discovery - Driving Strategic Improvements With Scientific Informatics

Adoption of a scientific informatics system is essential to the success of every drug discovery organisation. This article discusses how we can drive strategic improvements in biologics drug discovery using scientific informatics.

Raising The Bar On The Biologics Potential

In the quest for safe, efficacious and profitable therapies, pharma research is changing. There is continued pressure to fill the drug pipeline and, at the same time, globalisation of personalised medicines is complex, expensive and requires a significant time commitment.

The Chinese Biologics Drug Market: Demand and Execution

In the past decade, China's drug market has been expanding in double-digit percentages. This has brought about a huge increase in local drug makers and has lured multinational pharmaceutical companies to develop, manufacture and commercialise their drug products in China.

Balancing A Biologics Pipeline Portfolio

Research into groundbreaking biologic therapies has significantly shifted the diagnosis and treatment paradigms for many disease categories, particularly in oncology, autoimmune, inflammation and neurology.

Treating Rheumatoid Arthritis with Disease-Modifying Antirheumatic Drugs (DMARDs) and Biologics

Successful treatment paradigms for newly diagnosed rheumatoid arthritis (RA) now rely on aggressive pharmacotherapy approaches with disease-modifying antirheumatic drugs (DMARDs). Despite risks of toxicity and adverse effects, combination strategies with DMARDs are finding greater clinical utility and demonstrate attenuation in the disease progression of rheumatoid arthritis.